JP2021533142A5 - - Google Patents

Info

Publication number
JP2021533142A5
JP2021533142A5 JP2021505954A JP2021505954A JP2021533142A5 JP 2021533142 A5 JP2021533142 A5 JP 2021533142A5 JP 2021505954 A JP2021505954 A JP 2021505954A JP 2021505954 A JP2021505954 A JP 2021505954A JP 2021533142 A5 JP2021533142 A5 JP 2021533142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antigen
composition according
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021505954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533142A (ja
JP7460598B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045970 external-priority patent/WO2020033872A1/en
Publication of JP2021533142A publication Critical patent/JP2021533142A/ja
Publication of JP2021533142A5 publication Critical patent/JP2021533142A5/ja
Application granted granted Critical
Publication of JP7460598B2 publication Critical patent/JP7460598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505954A 2018-08-10 2019-08-09 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 Active JP7460598B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US62/717,435 2018-08-10
US201862764816P 2018-08-15 2018-08-15
US62/764,816 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (3)

Publication Number Publication Date
JP2021533142A JP2021533142A (ja) 2021-12-02
JP2021533142A5 true JP2021533142A5 (enExample) 2022-08-12
JP7460598B2 JP7460598B2 (ja) 2024-04-02

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505954A Active JP7460598B2 (ja) 2018-08-10 2019-08-09 膝および／または股関節痛の安全で効果的な処置用の医薬組成物

Country Status (10)

Country Link
US (2) US11472870B2 (enExample)
EP (1) EP3833687A1 (enExample)
JP (1) JP7460598B2 (enExample)
KR (1) KR20210043624A (enExample)
CN (1) CN112839956A (enExample)
AU (1) AU2019318556A1 (enExample)
CA (1) CA3108697A1 (enExample)
IL (1) IL280550B2 (enExample)
MX (1) MX2021001549A (enExample)
WO (1) WO2020033872A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) * 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2011227335B2 (en) * 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CA2875783C (en) * 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
IL266640B (en) * 2016-11-29 2022-09-01 Regeneron Pharma A pharmaceutical composition for averting opioid addiction

Similar Documents

Publication Publication Date Title
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2018512435A5 (enExample)
JP2013542194A5 (enExample)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
RU2012156938A (ru) Антитела против gdf8 человека
RU2013155906A (ru) Антитела анти-angptl3 и их применение
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
TW202311284A (zh) 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2019512472A5 (enExample)
JP2022536469A5 (enExample)
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
JP2021533142A5 (enExample)
JP2018529661A5 (enExample)
JP2024540226A5 (enExample)
AU2022200690B2 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP2023510199A5 (enExample)
JP2022534794A5 (enExample)
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
FI3880186T3 (fi) PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi
JP2022513029A5 (enExample)
JP2019535716A5 (enExample)
JP2023527200A5 (enExample)
JP2020535180A5 (enExample)